Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (174)	3/27/1998 12:59:00 AM
From: Robert Engel	Respond to of 340

It is good news both for patients and investors. The results of the study confirm earlier findings regarding relapses and more importantly it has now be shown that the drug slows progression of disability. It was stated in the press releases (company and clinician) that the drug thus constitutes a first line defense. That means it is not just second choice to Avonex.

To: Ariella who wrote (174)	3/27/1998 8:54:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 340

I am a Biogen investor, but try to look at things objectively. Still, the "evidence" that copaxone slows progression of MS was not conducted under the rigorous conditions of a clinical study, but was funded research at universities. Who funded the research? Hopefully, the findings are accurate for the sake of patients. But, when applying for approval in the US under the strict criteria that clinical studies impose, Teva was unable to show slower progression of the disease with Copaxone.